Caris Life Sciences, Inc. (CAI) Stock Price & Analysis
Caris Life Sciences, Inc. (CAI) closed at USD 31.76 on Thursday, October 15, 2026, up 4.97% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 30.26; the Oct 15, 2026 session ranged USD 28.8–32.15 on volume of 3,457,931 shares. Market capitalization is $8.98B, with a 52-week range of USD 14.19–33.65 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CAI.md
Key facts (CAI)
- Last four reported quarters (through Jun 30, 2026): revenue $990M, net income $105M (10.6% margin), free cash flow $124M (SEC filings).
- Valuation: P/E 85.4x.
- Analysts: Buy (mean 2.21 on a 1–5 scale) (14 analysts), mean target USD 31.62 (range 22–38).
- Total return with dividends: 1Y -0.6% vs S&P 500 +18.1%; 5Y +16.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD 0.02, revenue estimate $255M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CAI)
| USD | FY2025 | FY2025 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $306M | $412M | $812M | $990M |
| Operating income | -$320M | -$257M | $45.1M | $153M |
| Net income | -$341M | -$282M | -$68.1M | $105M |
| EPS (diluted) | -$13.24 | -$10.66 | -$3.22 | — |
| Free cash flow | -$298M | -$254M | $66.9M | $124M |
| Operating margin | -104.4% | -62.4% | 5.6% | 15.5% |
| Net margin | -111.5% | -68.4% | -8.4% | 10.6% |
| Revenue growth | — | +34.7% | +97.0% | — |
| Cash + short-term investments | — | $66.2M | $799M | — |
| Total debt | — | $380M | $379M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CAI)
P/E 85.4x · P/S 9.1x · P/FCF 72.4x · P/B 15.2x · FCF yield 1.38% · Earnings yield 1.17% · Buyback yield (TTM) 0.24%
Analysts (CAI)
Consensus Buy (mean 2.21 on a 1–5 scale), 14 analysts; mean target USD 31.62 (low 22, high 38).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | JP Morgan | Target raised | Overweight | $25 → $35 |
| 2026-10-13 | TD Cowen | Target raised | Buy | $30 → $36 |
| 2026-09-09 | UBS | Initiated | Neutral | $28 |
| 2026-08-06 | Evercore ISI Group | Target raised | Outperform | $25 → $26 |
| 2026-08-06 | BTIG | Target raised | Buy | $32 → $33 |
| 2026-08-05 | JP Morgan | Target lowered | Overweight | $30 → $25 |
| 2026-07-06 | Evercore ISI Group | Target lowered | Outperform | $30 → $25 |
| 2026-07-02 | BTIG | Reiterated | Buy | $32 |
Total return (dividends reinvested) (CAI)
| 1Y (from 2025-10-16) | 5Y (from 2025-06-16) | |
|---|---|---|
| Total return | -0.6% | +16.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -0.6% | +12.2% |
| Volatility (annualized) | 68.5% | 65.5% |
| Max drawdown | -54.5% (Oct 2025→May 2026) | -63.0% (Aug 2025→May 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 31.76 |
|---|---|
| Change | ▲ 4.97% (up) |
| Previous Close | USD 30.26 |
| Open | USD 29.5 |
| Day Range | USD 28.8 – 32.15 |
| 52-Week Range | USD 14.19 – 33.65 |
| Volume | 3,457,931 shares |
| Market Cap | $8.98B |
| Exchange | NMS |
Technical Analysis (CAI)
Nexqual's technical model rates CAI "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.22 (neutral) |
| vs SMA50 | Above (USD 26.86) |
| MACD | 0.92 (positive) |
Analyst Ratings (CAI)
Wall Street analysts rate CAI "Buy" based on 14 analysts, with a mean price target of USD 31.62 (range USD 22–38), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 31.62 |
| High Target | USD 38 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 10 / 4 / 0 |
Earnings (CAI)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.02 |
| Revenue Estimate | $254.67M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0 vs est 0.01 ▼ miss |
| 2026-03-31 | USD 0 vs est -0.02 ▲ beat |
| 2025-12-31 | USD 0.28 vs est 0.1 ▲ beat |
| 2025-09-30 | USD 0.08 vs est -0.14 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (CAI)
| Total Revenue | $989.60M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +45.40% |
| Gross Margin | +69.85% |
| Operating Margin | +10.21% |
| Profit Margin | +10.62% |
| ROE | +20.13% |
| Debt / Equity | 0.76 |
| Current Ratio | 5.53 |
| Total Cash | $793.12M |
| Total Debt | $452.40M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $66.89M (8.2% of revenue) |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (CAI)
Nexqual rates Caris Life Sciences, Inc.'s overall financial health "Strong" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Strong — Revenue +45% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 70%, operating 10% |
| Balance Sheet | Mixed — $793M cash vs $452M debt, net cash position |
| Cash Flow | Solid — FCF $67M (FY ended Dec 2025, 10-K), 8% margin |
| Efficiency | Strong — ROE 20%, ROA 8.8% |
Ownership (CAI)
| Insider Ownership | +48.79% |
|---|---|
| Institutional Ownership | +56.59% |
| Shares Outstanding | 282.68M |
| Float | 134.87M |
| Short % of Float | +12.06% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (CAI)
Caris Life Sciences, Inc. is led by David Dean Halbert (age 69), Chairman, CEO & Founder, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chairman, CEO & Founder | David Dean Halbert (age 69) |
|---|---|
| Executive Vice Chairman & Executive VP | Brian J. Brille (age 64) |
| President | David Spetzler M.B.A., M.S. (age 48) |
| Senior VP, CFO & Chief Accounting Officer | Luke Power (age 43) |
| Senior VP & CTO | Valeriy Domenyuk |
Major Backers & Investors (CAI)
Notable institutional backers of Caris Life Sciences, Inc. include FMR, LLC, J. H. Whitney Equity Partners VI, LLC, JPMorgan, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 10.94% |
| J. H. Whitney Equity Partners VI, LLC | 3.98% |
| JPMorgan | 3.5% |
| Coatue Management | 3.47% |
| Braidwell LP | 2.92% |
| T. Rowe Price | 2.76% |
| Fidelity | 2.71% |
| Sixth Street Partners Management Company, L.P. | 2.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.77% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TGTX | TG Therapeutics, Inc. | USD 56 | ▲ 3.05% |
| AXSM | Axsome Therapeutics, Inc. | USD 161.79 | ▲ 3.5% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.55 | ▼ 1.4% |
| CYTK | Cytokinetics, Incorporated | USD 63.92 | ▲ 3.73% |
| TWST | Twist Bioscience Corporation | USD 144.49 | ▼ 4.52% |
| KYMR | Kymera Therapeutics, Inc. | USD 108.14 | ▲ 1.37% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt